Kolja Reifenrath

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

D. Niederwieser, S. Scholl, C. Junghanss, 2021, Annals of Hematology.

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

W. Hiddemann, B. Dörken, A. Krämer, 2023, Annals of Hematology.

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

W. Hiddemann, A. Krämer, D. Niederwieser, 2016 .

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

G. Behre, D. Niederwieser, T. Lindner, 2014, Journal of Cancer Research and Clinical Oncology.

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

D. Niederwieser, S. Schwind, T. Lange, 2015, Journal of Cancer Research and Clinical Oncology.